WO1999061067B1 - Gene expression method - Google Patents

Gene expression method

Info

Publication number
WO1999061067B1
WO1999061067B1 PCT/US1999/011697 US9911697W WO9961067B1 WO 1999061067 B1 WO1999061067 B1 WO 1999061067B1 US 9911697 W US9911697 W US 9911697W WO 9961067 B1 WO9961067 B1 WO 9961067B1
Authority
WO
WIPO (PCT)
Prior art keywords
factor
expression
nucleic acid
cell
neural
Prior art date
Application number
PCT/US1999/011697
Other languages
French (fr)
Other versions
WO1999061067A1 (en
WO1999061067A8 (en
Inventor
Joseph C Glorioso
Darren P Wolfe
William F Goins
Original Assignee
Univ Pittsburgh
Joseph C Glorioso
Darren P Wolfe
William F Goins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh, Joseph C Glorioso, Darren P Wolfe, William F Goins filed Critical Univ Pittsburgh
Priority to AU42103/99A priority Critical patent/AU4210399A/en
Priority to EP99925911A priority patent/EP1082140A1/en
Publication of WO1999061067A1 publication Critical patent/WO1999061067A1/en
Publication of WO1999061067B1 publication Critical patent/WO1999061067B1/en
Publication of WO1999061067A8 publication Critical patent/WO1999061067A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a method of delivering a factor to non-neural tissue and a method of treating neuropathy. The method involves introducing an expression cassette including a nucleic acid for expression involved in the production of the factor into a neural cell, within which the nucleic acid for expression is expressed, and from which the factor is therefore secreted. The method also provides a method of promoting long-term gene expression in vivo, by employing a herpesvirus to deliver a transgene to a desired tissue of a host animal. The method also permits repeat administration of the transgene.

Claims

18AMENDED CLAIMS[received by the International Bureau on 17 December 1999 (17.12.99); original claims 1-20 replaced by new claims 1-27 (2 pages)]
1. A method of delivering a factor to non-neural tissue, said method comprising introducing into a neural cell an expression cassette comprising a nucleic acid for expression involved in the production of said factor such that said factor is produced and secreted from said cell.
2. The method of claim 1, wherein said neural cell communicates with said non-neural tissue such that said factor is secreted into said non-neural tissue.
3. The method of claim 1 or 2, wherein said factor is disseminated systemically.
4. The method of claim 1 , wherein said factor is first secreted into cerebrospinal fluid and then crosses the blood-brain barrier.
5. A method of treating neuropathy, comprising introducing into a neural cell an expression cassette comprising a nucleic acid for expression involved in the production of a neuroactive factor such that said factor is produced within said cell to treat said neuropathy.
6. The method of claim 5, wherein said neuropathy is associated with diabetes.
7. The method of any of claims 1-6, wherein said neural cell is within the peripheral nervous system.
8. The method of any of claims 1 -6, wherein said neural cell is within the central nervous system.
9. A method of treating urinary incontinence, comprising introducing into a cell within the urinary track an expression cassette comprising a nucleic acid for expression involved in the production of a factor such that said factor is produced to treat said urinary incontinence.
10. The method of claim 9, wherein said cell is within a bladder.
11. The method of claim 9 or 10, wherein said cell is a neural cell.
12. The method of any of claims 9-11, wherein said factor is a neuroactive factor.
13. The method of any of claims 1-12, wherein said expression cassette contains a LAP2 promoter.
14. The method of any of claims 1-13, wherein said expression cassette is contained within a viral vector and is introduced into said cell by infecting said cell with said viral vector.
15. The method of claim 14, wherein said vector is a herpesviral vector.
16. The method of claim 14 or 15, wherein said vector has an inactivating mutation in at least one viral locus essential for viral replication. 19
17. The method of any of claims 1-16. wherein said factor is a protein, and said nucleic acid for expression encodes said protein.
18. The method of any of claims 1-16, wherein said nucleic acid for expression encodes an enzyme for synthesizing said factor.
19. The method of any of claims 1-18. wherein said factor is a trophic factor.
20. The method of any of claims 1-19. wherein said factor is selected from the group of factors consisting of nerve growth factor, ciliary neurotrophic factor, brain derived neurotrophic factor, glial derived neurotrophic factor, and neurotrophin-3.
21. A method of expressing a nucleic acid for expression in vivo, which comprises introducing into a tissue of an animal a replication defective herpesviral vector comprising a non-herpes nucleic acid for expression and a promoter operatively linked to said nucleic acid for expression, whereby said nucleic acid for expression is expressed in vivo for at least about 40 days.
22. The method of claim 21, further comprising again introducing into said animal a second replication defective herpesviral vector comprising a non-herpes nucleic acid for expression and a promoter operatively linked to said nucleic acid for expression, whereby said nucleic acid for expression is again expressed in vivo for at least about 40 days.
23. The method of claim 21 or 22, wherein said nucleic acid for expression is expressed for at least about 100 days.
24. The method of any of claims 21-23. wherein said nucleic acid for expression is expressed for at least about 200 days.
25. The method of any of claims 21-24. wherein said nucleic acid for expression is expressed for at least about 300 days.
26. The method of any of claims 21-25. wherein said nucleic acid for expression encodes a protein.
27. The method of any of claims 21-26. wherein said promoter is a LAP2 promoter.
PCT/US1999/011697 1998-05-27 1999-05-27 Gene expression method WO1999061067A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU42103/99A AU4210399A (en) 1998-05-27 1999-05-27 Gene expression method
EP99925911A EP1082140A1 (en) 1998-05-27 1999-05-27 Gene expression method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8693598P 1998-05-27 1998-05-27
US60/086,935 1998-05-27

Publications (3)

Publication Number Publication Date
WO1999061067A1 WO1999061067A1 (en) 1999-12-02
WO1999061067B1 true WO1999061067B1 (en) 2000-02-10
WO1999061067A8 WO1999061067A8 (en) 2001-03-15

Family

ID=22201850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011697 WO1999061067A1 (en) 1998-05-27 1999-05-27 Gene expression method

Country Status (3)

Country Link
EP (1) EP1082140A1 (en)
AU (1) AU4210399A (en)
WO (1) WO1999061067A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580699B2 (en) 2014-04-17 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use

Also Published As

Publication number Publication date
EP1082140A1 (en) 2001-03-14
WO1999061067A1 (en) 1999-12-02
WO1999061067A8 (en) 2001-03-15
AU4210399A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
EP0763107B1 (en) Pantropic neurotrophic factors
Emerich et al. Implants of polymer‐encapsulated human NGF‐secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons
Gage et al. NGF receptor reexpression and NGF-mediated cholinergic neuronal hypertrophy in the damaged adult neostriatum
EP0802800B1 (en) Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules
US8101571B2 (en) Treatment methods using NGF variants
Shen et al. Recent progress in studies of neurotrophic factors and their clinical implications
Brooks et al. Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector
Kordower et al. TRK‐immunoreactivity in the monkey central nervous system: Forebrain
KR102598130B1 (en) Eukaryotic expression vector containing regulatory elements of the globin gene cluster
WO1995027512A3 (en) Compositions and methods for gene therapy to treat disease
US7144983B1 (en) Pantropic neurotrophic factors
WO1999061067B1 (en) Gene expression method
Mrzljak et al. Low-affinity nerve growth factor receptor (p75NGFR)-and choline acetyltransferase (ChAT)-immunoreactive axons in the cerebral cortex and hippocampus of adult macaque monkeys and humans
AU2002300365B2 (en) NGF Variants
Hefti et al. Pharmacology of nerve growth factor in the brain
Hefti Nerve growth factor promotes survival of septal cholinergic neurons after injury
Bowes et al. Continuous intrathecal fluid infusions elevate nerve growth factor levels and prevent functional deficits after spinal cord ischemia
Kordower et al. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?
DE69233339T2 (en) Expression increase by gene targeting into endogenous retrovirus-like sequences
WO2000028010A3 (en) The genetic determination of genes and its use for the prophylaxis and therapy of diseases
CN110218701A (en) It is a kind of screen miRNA adjusting control agent cell model and application
Yamamoto et al. Expression of cytokines in the dorsal root ganglion cell body in an experimental model of entrapment neuropathy
CN116262139A (en) Method for regulating vascular endothelial cell heterogeneity through blue-spot nuclei and peripheral regions thereof
FACTOR HUMAN ERYTHROID P55 NUCLEIC ACIDS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09701156

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999925911

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999925911

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 48/99 UNDER (81) ADD "ZA"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1999925911

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999925911

Country of ref document: EP